NeoGenomics Stock News

While the top- and bottom-line numbers for NeoGenomics (NEO) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compar

NeoGenomics (NEO) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.09 per share a year ago.

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NeoGenomics (NEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The consensus price target hints at a 43.3% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima

The consensus price target hints at a 29.6% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima

While the top- and bottom-line numbers for NeoGenomics (NEO) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics com

NeoGenomics, Inc (NEO) Q4 2023 Earnings Call Transcript

NeoGenomics (NEO) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.06 per share a year ago.

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc., will report its fourth quarter and full year 2023 financial results on Tuesday, February 20, 2024.

NEO, WIX and LNW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 9, 2024.

NEO, WIX, LNW, TM and RBB have been added to the Zacks Rank #1 (Strong Buy) List on January 9, 2024.

FT. MYERS, FL / ACCESSWIRE / December 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced new data highlighting its RaDaR® assay for minimal residua

Although the revenue and EPS for NeoGenomics (NEO) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall

NeoGenomics, Inc (NASDAQ:NEO ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 AM ET Company Participants Kendra Sweeney - VP, IR Chris Smith - CEO Jeff Sherman - CFO Vishal Sikri - President,